Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423107 | 0.91 | CRHR1 (0.56) | CRHR1MEN1POLBKMT2A | |
| SCHEMBL5423317 | 0.88 | CRHR1 (0.56) | CRHR1MEN1POLBKMT2ATP53 | |
| SCHEMBL6203614 | 0.85 | CRHR1 (0.70) | CRHR1 | |
| SCHEMBL5406509 | 0.82 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5417862 | 0.80 | CRHR1 (0.49) | CRHR1MEN1KMT2ATP53MAPT | |
| SCHEMBL5414869 | 0.79 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL5406519 | 0.79 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL6201263 | 0.77 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL5531126 | 0.77 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL6202812 | 0.77 | CRHR1 (0.62) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1255740-B1 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| EP-1554258-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1500653-A1 | Substituted arylpyrazines | Neurogen Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | disclosed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885MEN1 2942/4885POLB 4841/4885 |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | CRHR1 5/4885MEN1 3330/4885POLB 4558/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885MEN1 2942/4885POLB 4841/4885 |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | CRHR1 5/4885MEN1 3330/4885POLB 4558/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885MEN1 3382/4885POLB 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.